What is the efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir (Viekira Pak) for hepatitis C virus (HCV) infection genotype 1b infection?

Updated: Oct 07, 2019
  • Author: Vinod K Dhawan, MD, FACP, FRCPC, FIDSA; Chief Editor: BS Anand, MD  more...
  • Print

HCV genotype 1b infection cure rates for the ombitasvir/paritaprevir/ritonavir and dasabuvir combination included the following:

  • No cirrhosis: SVR12 rates were 99% for 12 weeks of treatment with ribavirin (PEARL-III Study) [124]
  • Cirrhosis: SVR12 rates were 98.5% in the 12-week arm (with ribavirin) and 100% in the 24-week arm; prior treatment null responders had lower SVR rates (TURQOUISE-II Study) [125]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!